"I believe that we can eradicate heart attacks from this world...If we can leverage these tools to accomplish those three goals, whether it's in coronary heart disease, valvular heart disease, myocardial disease, et cetera, et cetera, I think that's going to not be a slight improvement. I think it's going to be a game changer in terms of improving patient care and outcomes." ~ Jim Min, Founder and CEO at Cleerly

In healthcare, there is a constant need for innovation and improvement. One company making significant strides in this field is Cleerly Health, founded by Jim Minh. In a recent discussion, Jim and Ramin Farhood, a leading cardiologist, delved into building a research-based business organization and transitioning from prevention in the clinic to prevention at scale. They also explored the challenges of driving behavior change in the medical community to enable prevention. We will closely examine their insightful conversation and the groundbreaking work being done at Cleerly Health.

Building an Asset in Clinical Practice

Cleerly Health, founded in 2017, has emerged as a prominent player in the healthcare industry. With a focus on creating a standardized and personalized care pathway for coronary heart disease, the company leverages imaging and end-to-end artificial intelligence (AI) to achieve its goals. Cleerly Health aims to provide a comprehensive evaluation, education, treatment, and tracking system for patients with heart disease

Jim, a former cardiologist at Cornell Medical College and New York Presbyterian Hospital, has firsthand experience with the effectiveness of personalized medicine in cardiology. However, he realized the need to scale this approach and automate certain processes for more accurate insights. This realization led to the founding of Cleerly Health, with the goal of optimizing personalized medicine in cardiology using imaging technology and AI.

One of the critical challenges that Cleerly Health faced during its early stages was the feasibility of its approach. Developing algorithms, obtaining FDA clearance, and securing reimbursement from insurance payers were all significant hurdles. Despite these challenges, the founders remained determined to change the standard of care for heart disease prevention radically.

Cleerly Health focused on building a business that had a strong research foundation. This foundation was crucial for obtaining coverage and reimbursement from insurance providers. The company realized that in the healthcare industry, high-quality science is necessary to drive commercial growth.

Driving Behavior Change in the Medical Community

To achieve its ultimate goal of preventing heart disease and heart attacks, Cleerly Health adopted a disease-based approach to cardiovascular evaluation and treatment. This approach places emphasis on treating individuals with disease rather than waiting for symptomatic manifestations. Currently, the majority of heart attack patients do not exhibit symptoms before their events, underscoring the need for a shift in the current symptom-driven model.

The company is currently focused on treating the symptomatic population but is also pursuing a large-scale randomized control trial called the Transform study. This trial aims to study the efficacy of Cleerly Health's approach in the asymptomatic population. By expanding patient identification and treating individuals proactively, they hope to improve outcomes and reduce costs in the long run.

The Future of Cardiology and Digital Therapeutics

While Cleerly Health is making significant strides in the field of cardiology, it is not the only player focused on improving patient outcomes. Verily, a company that combines technology, science, and healthcare, is also working on developing technologies for earlier disease detection, interventions, and more personalized healthcare. Verily has developed advanced algorithms that analyze medical imaging data to predict the risk of cardiovascular disease.

Adopting digital therapeutics, such as software-based interventions, has also gained momentum. These interventions can improve patient outcomes, reduce healthcare costs, and increase access to care. However, challenges and barriers still need to be overcome for widespread adoption, including reimbursement and data privacy issues.

Cleerly Health is at the forefront of revolutionizing the field of cardiology. Through their innovative approach, leveraging imaging and artificial intelligence, they are working towards standardizing and personalizing care pathways for coronary heart disease. Their focus on comprehensive evaluation, standardized care, and personalized treatment highlights their commitment to improving patient outcomes and reducing healthcare costs.

As the future of cardiology unfolds, collaboration between companies like Cleerly Health and Verily, along with healthcare providers and regulators, will be crucial. The healthcare industry can strive toward a future where diseases like heart attacks can be eradicated by harnessing the power of advanced imaging and digital therapeutics.

Join us in our next episode as we continue exploring captivating topics in the dynamic world of biotech.

Until then, keep pushing the boundaries of innovation and maximizing the value of your therapeutics.

We hope you enjoyed yet another informative Episode of the Emerging Biotech Leader. Please leave us a review or rate us on Apple or Spotify.